For
the quarter ending March 2022, consolidated net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 8.76% to Rs 809.63 crore compared to quarter ended march 2021.
Operating profit margin has jumped from 21.05% to 21.64%, leading to 11.83% rise in operating profit to Rs 175.22 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 18.84% to 18.74%. Purchase of finished goods cost fell from 27.09% to 23.29%. Employee cost decreased from 19.36% to 17.72%. Other expenses rose from 14.63% to 18.09%. Other income fell 36.62% to Rs 18.76 crore. PBIDT rose 4.13% to Rs 193.98 crore. Provision for interest fell 55.56% to Rs 0.28 crore. Loan funds declined from Rs 34.62 crore as of 31 March 2021 to Rs 20.07 crore as of 31 March 2022. Inventories declined from Rs 546.70 crore as of 31 March 2021 to Rs 534.70 crore as of 31 March 2022. Sundry debtors were lower at Rs 205.24 crore as of 31 March 2022 compared to Rs 215.60 crore as of 31 March 2021. Cash and bank balance rose to Rs 2,484.51 crore as of 31 March 2022 from Rs 1,157.96 crore as of 31 March 2021.
PBDT rose 4.34% to Rs 193.7 crore. Provision for depreciation fell 13.18% to Rs 15.35 crore. Fixed assets declined from Rs 356.75 crore as of 31 March 2021 to Rs 326.65 crore as of 31 March 2022. Intangible assets declined from Rs 43.36 crore to Rs 34.50 crore.
Profit before tax grew 6.18% to Rs 178.35 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 262.51 crore, compared to Rs 45.32 crore. Effective tax rate was 126.30% compared to 92.55%.
Minority interest was nil in both the periods. Net loss attributable to owners of the company stood at Rs 54.66 crore compared to net profit of Rs 3.65 crore. Profit from discontinued operations net of tax stood at Rs 1273.71 crore compared to profit of Rs 10.68 crore.
In Q4 FY22, Net profit after discontinued operations went up 8406.98% to Rs 1219.05 crore.
Equity capital stood at Rs 169.41 crore as of 31 March 2022 to Rs 169.41 crore as of 31 March 2021. Per share face Value remained same at Rs 10.00.
Promoters’ stake was 75.00% as of 31 March 2022 ,compared to 75.00% as of 31 March 2021 .
Full year results analysis.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 12.05% to Rs 3278.03 crore. Operating profit margin has jumped from 20.45% to 23.24%, leading to 27.37% rise in operating profit to Rs 761.88 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 15.92% to 18.73%. Purchase of finished goods cost fell from 27.77% to 22.36%. Employee cost decreased from 20.79% to 18.70%. Other expenses rose from 15.33% to 16.85%. Other income fell 31.47% to Rs 75.78 crore. PBIDT rose 18.19% to Rs 837.66 crore. Provision for interest fell 43.34% to Rs 2 crore. Loan funds declined from Rs 34.62 crore as of 31 March 2021 to Rs 20.07 crore as of 31 March 2022. Inventories declined from Rs 546.70 crore as of 31 March 2021 to Rs 534.70 crore as of 31 March 2022. Sundry debtors were lower at Rs 205.24 crore as of 31 March 2022 compared to Rs 215.60 crore as of 31 March 2021. Cash and bank balance rose to Rs 2,484.51 crore as of 31 March 2022 from Rs 1,157.96 crore as of 31 March 2021.
PBDT rose 18.50% to Rs 835.66 crore. Provision for depreciation fell 13.24% to Rs 68.19 crore. Fixed assets declined from Rs 356.75 crore as of 31 March 2021 to Rs 326.65 crore as of 31 March 2022. Intangible assets declined from Rs 43.36 crore to Rs 34.50 crore.
Profit before tax grew 22.48% to Rs 767.47 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 398.28 crore, compared to Rs 166.72 crore. Effective tax rate was 51.12% compared to 36.72%.
Minority interest was nil in both the periods. Net profit attributable to owners of the company increased 32.55% to Rs 380.77 crore. Profit from discontinued operations net of tax stood at Rs 1313.95 crore compared to profit of Rs 70.88 crore.
In FY22, Net profit after discontinued operations went up 373.19% to Rs 1694.72 crore.
Equity capital stood at Rs 169.41 crore as of 31 March 2022 to Rs 169.41 crore as of 31 March 2021. Per share face Value remained same at Rs 10.00.
Promoters’ stake was 75.00% as of 31 March 2022 ,compared to 75.00% as of 31 March 2021 .
Cash flow from operating activities increased to Rs 810.74 crore for year ended March 2022 from Rs 577.92 crore for year ended March 2021. Cash flow used in acquiring fixed assets during the year ended March 2022 stood at Rs 34.64 crore, compared to Rs 44.23 crore during the year ended March 2021.
Dividend update
The Board has
recommended a dividend of Rs 90 (including special dividend of Rs 60) per equity
share on face value of Rs 10 each for the year ended 31 st March 2022. Company
has fixed Friday, 8th July, 2022 as the Record Date.